Eli Lilly has filed three new separate lawsuits accusing vendors and a medical spa of selling knock-off versions of their ...

The company is suing some online vendors and medical spas for selling copycats of a weight loss and diabetes drug.

Though Lilly has been in the spotlight for the success of its GLP-1 drugs, the pharma giant has also been investing in a corporate brand campaign to boost its overall reputation.

Currently, financial markets are experiencing a mix of optimism and caution as investors react to changing economic ...

Weaver Capital Management LLC lessened its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 1.0% in the 3rd quarter ...

Altus Wealth Group LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 45.4% in the 3rd ...

Ahead of the event, analysts expect LLY to report a profit of $1.98 per share on a diluted basis, up significantly from $0.10 per share in the year-ago quarter. The company has consistently surpassed ...

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...

But another titan has started to inflate. Ladies and gentlemen, let’s talk about Eli Lilly. There’s something curious about the chart below. Nvidia, the poster child of the AI revolution ...

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high ...

Senators led by Sen. Dick Durbin (D-Ill.) on Monday demanded answers from Pfizer and Eli Lilly about their relationship with the telehealth prescribers they point patients to from their websites ...